New antibiotics.
Three broad-spectrum antibiotics are reviewed, each from a different class. Meropenem is closely related to imipenem and was recently approved for use in children. Its advantages over imipenem include greater activity against gram-negative bacteria and lack of association with seizures. Cefepime is a fourth generation cephalosporin with the gram-positive activity of cefotaxime and the gram-negative spectrum of ceftazidime. Trovafloxacin is a fluoroquinolone with an exceptionally broad antibacterial spectrum. Meropenem is approved for use in children, cefepime is approved for use in adults only, and trovafloxacin is still undergoing clinical trials. These agents should be reserved for treatment of serious infections, especially those in immunocompromised patients or polymicrobial infections.
Friedland
I R
IR
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75235-9063, USA.
Lutsar
I
I
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000077723:Cefepime; D002511:Cephalosporins / Q000627:therapeutic use*; D002648:Child; D024841:Fluoroquinolones; D006801:Humans; D016920:Meningitis, Bacterial / Q000188:drug therapy; D000077731:Meropenem; D009287:Naphthyridines / Q000627:therapeutic use*; D013845:Thienamycins / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D009287:Naphthyridines; D013845:Thienamycins; D000077723:Cefepime; C080163:trovafloxacin; D000077731:Meropenem